Abu Dhabi-based Arcera Life Sciences has pledged more than $1 billion in totality for the rights to potentially take Innogen’s China-approved GLP-1, efsubaglutide alfa, international.
Per the agreement, Arcera is gaining exclusive development and commercialization rights to efsubaglutide alpha in its priority markets of Africa, Eastern Europe, Latin America and the Middle East, leaving the rest of the world to Innogen.
Arcera expects to hand Innogen an initial $38 million near-term milestone payments for the license, including an upfront, non-refundable payout of $15 million. As net sales grow, Innogen stands to earn a double-digit percentage in royalties, plus additional revenue-based milestone payments, accounting for a total potential deal value exceeding $1 billion, the companies said Thursday.
Founded in 2024, Arcera specializes in generics, established medicines and licensing innovative therapies beyond the saturated Western markets. The new partnership simultaneously allows Arcera to provide an innovative metabolic therapy and Innogen to leverage Arcera’s market access and regulatory expertise for efsubaglutide alfa’s planned global expansion.
“Cardiometabolic diseases remain among the most pressing healthcare challenges in the markets we serve,” Isabel Afonso, chief executive officer of Arcera Life Sciences, said in a statement.
In mainland China, efsubaglutide alfa is already approved to treat type 2 diabetes and under study as a weight loss treatment. Late-stage data has shown that when added to metformin, the drug helped reduce patients' HbA1c by 1.8% at 24 weeks, compared to a 0.74% reduction seen on placebo.
Innogen has also run clinical trials in China and Australia testing efsubaglutide alfa in patients with obesity. In Chinese adults, 18 weeks on the weekly treatment reduced body weight by 10.6% and increased muscle-to-fat ratio by 45.3%. Liver fat content was reduced by more than 50%, according to the companies' release this week.
"We are delighted to establish this collaboration with Arcera, which represents an important step in Innogen's international expansion,” Qinghua Wang, M.D., Ph.D., the founder, chairman and chief executive officer of Innogen, said in a statement.
“By combining Innogen's scientific innovation with Arcera's strengths in international regulatory affairs and commercialization, we aim to broaden access to differentiated therapies and ultimately improve the quality of life of patients around the world,” he added.
The licensing arrangement lands as competition continues to heat up in Innogen’s home territory of China. Last week, GLP-1 drugs from Pfizer and China-based Innovent Biologics were added to China’s 2027 drug reimbursement list as treatments for type 2 diabetes, alongside existing options from Novo, Lilly and Innogen.
Novo’s semaglutide has historically led the pack in diabetes and weight loss sales, the latter of which is limited to out-of-pocket pay since its not covered by the Chinese health system. But the Danish drugmaker’s dominance is fading amid growing competition and Chinese patent expirations, creating an opportunity for the growing number of rivals to capture market share.
Also last week, Lilly’s Foundayo was approved in China, adding the country’s first oral weight loss option to the mix and notably beating Novo’s Wegovy pill to the punch.